Navigation Links
Study points to potential new drug for type 2 diabetes
Date:3/15/2010

COLUMBUS, Ohio An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

The drug consists of a synthetic molecule that stops the biological activity of a protein called macrophage migration inhibitory factor, or MIF. This protein is implicated in a number of diseases because it is associated with the production of inflammation in the body.

The researchers first determined that mice that have been genetically engineered not to carry the MIF protein are less likely to develop symptoms of Type 2 diabetes. This finding suggested that MIF indeed has a role in at least two hallmarks of diabetes: impaired blood sugar control and the presence of other inflammatory proteins.

The scientists then treated diabetic mice with the investigational drug and found that most animals showed lower blood sugar levels and reduced inflammatory proteins in their blood when compared to untreated mice with Type 2 diabetes.

"We also found that if we stopped administering the drug, then the blood sugar level would go up," said Abhay Satoskar, associate professor of pathology at Ohio State University and senior author of the study. "This does not present a cure for diabetes, but we think, if it is approved in humans, that it has potential to become an oral drug taken for the long term to control a very common symptom of the disease."

The researchers supported their animal findings by measuring proteins and hormones in blood samples from a small group of people with Type 2 diabetes and healthy human participants for comparison. The patients with diabetes had significantly higher levels of MIF in their blood than did the healthy patients, as well as higher levels of two compounds that contribute to inflammation and insulin resistance.

"All
'/>"/>

Contact: Abhay Satoskar
satoskar.2@osu.edu
614-292-3243
Ohio State University
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Study opens new avenue for developing treatments for genetic muscle-wasting disease
2. Clemson researcher receives grant to study engineering enrollment of women, minorities
3. VAI researchers develop tool to help study prostate cancer
4. Students perceptions of Earths age influence acceptance of human evolution, says U of Minn. study
5. Study finds that low-income women living in small cities have higher chance of obesity
6. ARS study provides a better understanding of how mosquitoes find a host
7. Musk ox population decline due to climate, not to humans, study finds
8. Study shows potential for using algae to produce human therapeutic proteins
9. Study identifies key cause of chronic leukemia progression
10. Study shows woody plant encroachment has increased stream flow in the Edwards Plateau
11. New study shows teens who drink 100 percent fruit juice have more nutritious diets overall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
(Date:8/28/2014)... N.C. -- Scientists have identified the developmental on-off switch ... that produce more than two-thirds of the world,s naturally ... be to see whether it is possible to manipulate ... , The study, appearing August 28 in ... small molecule called cyclic-di-GMP and a larger protein called ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... MINNETONKA, Minn., Feb. 8, 2011 MedNet Solutions, ... in clinical study management systems, is pleased to ... the company,s flagship eClinical solution.  The ENLIGHTEN ... and easy-to-use electronic data capture (EDC) and clinical ...
... of the turtle world swimming farther, diving deeper and ... But for all their toughness, they have still suffered a ... Ocean over the last 20-plus years, largely at the hands ... tagging and tracking the turtles are providing insights into their ...
... their ability to exhibit the "Cheerios effect" when they move ... together like Cheerios swimming in milk in a cereal bowl ... has made Virginia Tech engineers speculate about the possible impacts ... the journal, Soft Matter , a publication of the ...
Cached Biology News:MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution 2Why leatherback turtles linger in South Pacific Gyre, and why it matters 2Why leatherback turtles linger in South Pacific Gyre, and why it matters 3Why leatherback turtles linger in South Pacific Gyre, and why it matters 4When worms stick together and swim on thin water, what happens and why does it matter? 2
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... N.Y. Researchers at Rensselaer Polytechnic Institute have ... of gold that measure only billionths of a ... equipment and works on nearly any surface including ... and semiconductor manufacturing. Sang-Kee Eah, assistant professor ...
... June 16 Trans World Alloys (TWA), one of the country,s ... Brennan has joined the company, as its new Chief Operating Officer. ACCORDING ... years experience in the metal business in a variety of areas." , ... Ed has attended the University of ...
... , , ... Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems and ... the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual ... 16-19, 2010 , in San Francisco, CA. Staccato(TM) will add ...
Cached Biology Technology:Researchers develop ultra-simple method for creating nanoscale gold coatings 2Ed Brennan - New C.O.O. of Trans World Alloys 2Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 2Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 3Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 4
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: